Article info

Download PDFPDF

Follow up of mortality and incidence of cancer 1952–98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes
  1. Correspondence to:
 Dr C R Muirhead, National Radiological Protection Board, Chilton, Didcot, Oxon OX11 0RQ, UK;
 colin.muirhead{at}nrpb.org
View Full Text

Citation

Muirhead CR, Bingham D, Haylock RGE, et al
Follow up of mortality and incidence of cancer 1952–98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes

Publication history

  • Accepted November 7, 2002
  • First published March 1, 2003.
Online issue publication 
March 01, 2003
  •  
    Follow up of mortality and incidence of cancer 1952�98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes
    C R Muirhead, D Bingham, R G E Haylock, J A O'Hagan, A A Goodill, G L C Berridge, M A English, N Hunter, and G M Kendall
     

    Web-only Tables

    Table S1
    Test participants and controls by Service or employer, rank or social class and, for the Services, whether or not on National Service
    [View PDF]
     

    Table S2 Observed deaths (Obs) and standardised mortality ratios (SMR) among test participants and controls by time since start of first test participation and for broad causes of death, plus leukaemia and multiple myeloma
    [View PDF]
     

    Table S3 Observed deaths and SMRs among test participants and controls, and RRs of mortality in test participants compared with controls, for 27 distinct types of cancer.  For leukaemia the whole follow-up period and the period 2 to 25 years after start of first test participation are considered, and for other specific cancers the period more than 10 years after start of first test participation is considered
    [View PDF]
     

    Table S4 Number of incident cancers observed (I) and expected (EI) for monitored test participants by dose category, for selected types of cancer.  For leukaemia the whole follow-up period and the period 2-25 years after start of first test participation are considered.  For other neoplasms the period more than 10 years after start of first test participation is considered
    [View PDF]
     

    Table S5 Numbers of incident cancers among test participants and controls, and RRs of incident cancer in test participants compared with controls. For leukaemia the whole follow-up period and the period 2-25 years after start of the first test participation are considered.  For other neoplasms the period more than 10 years after start of first test participation is considered
    [View PDF]

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.